May 6, 2020 / 12:08 PM / 19 days ago

BRIEF-Magenta Therapeutics And Avrobio Collaborate To Evaluate Targeted Antibody-Drug Conjugate

May 6 (Reuters) - AVROBIO Inc:

* MAGENTA THERAPEUTICS AND AVROBIO ANNOUNCE COLLABORATION TO EVALUATE TARGETED ANTIBODY-DRUG CONJUGATE AS A POTENTIAL CONDITIONING REGIMEN FOR LENTIVIRAL GENE THERAPIES

* MAGENTA THERAPEUTICS INC - CO & AVROBIO WILL JOINTLY EVALUATE MGTA-117 IN CONJUNCTION WITH ONE OR MORE OF AVROBIO’S INVESTIGATIONAL GENE THERAPIES

* MAGENTA THERAPEUTICS - UNDER COLLABORATION, EACH COMPANY WILL RETAIN ALL COMMERCIAL RIGHTS TO THEIR RESPECTIVE PROGRAMS

* MAGENTA THERAPEUTICS INC - MAGENTA WILL RETAIN ALL COMMERCIAL RIGHTS TO MGTA-117

* MAGENTA THERAPEUTICS -AVROBIO WILL RETAIN ALL COMMERCIAL RIGHTS TO ITS GENE THERAPIES

* MAGENTA THERAPEUTICS - AVROBIO WILL BE RESPONSIBLE FOR CLINICAL TRIAL COSTS RELATED TO EVALUATION OF MGTA-117 WITH AVROBIO’S GENE THERAPIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below